Spike Protein News and Research

RSS

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

An encouraging new study describes a promising new therapeutic antibody that shows potent neutralizing activity against SARS-CoV-2, the causative agent of COVID-19.

15 Jan 2021

Lab study reveals effective treatment for COVID-19

A new potential therapy for COVID-19 developed by researchers at Rush University Medical Center has shown success in preventing the disease's symptoms in mice.

14 Jan 2021

Study suggests SARS-CoV-2 could affect aquatic wildlife

Researchers have found that oxidative stress and neurotoxicity biomarkers increased in tadpoles exposed to synthetic SARS-CoV-2 spike protein peptides.

14 Jan 2021

New tests may help reveal the transcriptome of SARS-CoV-2 and predict disease course

As the COVID-19 pandemic continues to infect people in their hundreds of thousands around the world, a new study describes a panel of novel tests for genomic (g) and subgenomic (sg) mRNAs generated by SARS-CoV-2. Most assays in use at present are either qualitative or semi-quantitative, and cannot evaluate the transcription molecules in detail.

14 Jan 2021

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

Many patients with COVID-19 have shown neurological complications, leading to scientific interest in the role played by its causative pathogen, SARS-CoV-2, in brain inflammation. A new study has described the absence of neuroinflammation in cerebrospinal fluid (CSF).

14 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

The unchecked advance of COVID-19 has made it a top public health priority to produce a vaccine capable of inducing a safe and powerful protective response against its causative pathogen: SARS-CoV-2. An encouraging new study shows the immunogenicity, safety, and protective efficacy, of a Newcastle disease virus (NDV)-based intranasal vector vaccine in animal studies.

14 Jan 2021

Study identifies features of potent SARS-CoV-2 neutralizing antibodies

Researchers at Columbia University have provided important insights into features of viral binding and recognition within a class of potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Jan 2021

Moderna to develop three new mRNA-based vaccines against HIV, influenza, and the Nipah virus

Morderna has announced plans to develop a range of new mRNA-based vaccines against other viruses, including the influenza virus, human immunodeficiency virus (HIV), and the Nipah virus.

13 Jan 2021

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

Researchers from the University of Cambridge and the Pirbright Institute in the UK have identified key genetic changes in SARS-CoV-2 that may be responsible for the virus’s jump from bats to humans. The team also determined which animals contain cellular receptors that allow the virus to enter cells more effectively, zoning in on potential animals that acted as an intermediary host in facilitating SARS-CoV-2’s zoonosis.

13 Jan 2021

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

A team of scientists conducted structural analysis of a newly emerged UK variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They present evidence that suggests that while the new variant has increased infectivity it is not resistant to neutralizing antibodies.

13 Jan 2021

Could fenofibrate be an effective antiviral against SARS-CoV-2?

The resurgence of COVID-19 pandemic, caused by the SARS-CoV-2, has led to renewed efforts to find effective antivirals, both newly developed or repurposed drugs. A study reports the efficacy of the cholesterol-reducing drug fenofibrate in reducing infection rates of SARS-CoV-2 in cultured cells.

13 Jan 2021

Researchers develop novel antibody fragments against SARS coronavirus-2

An international research team led by the University of Bonn (Germany) has identified and further developed novel antibody fragments against the SARS coronavirus-2. These "nanobodies" are much smaller than the classic antibodies used to treat US President Donald Trump, for example.

13 Jan 2021

New publication describes DiosCURE’s multivalent single-chain antibodies to inactivate SARS-CoV-2

DiosCURE SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE.

13 Jan 2021

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.

12 Jan 2021

Intranasal vaccination effectively reduces viral shedding of SARS-CoV-2 in monkeys

A new preprint that appeared on the bioRxiv server reports that intranasal vaccination with the D614G variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus monkeys reduces viral shedding. This is an experiment in non-human primates (NHP), and its extrapolation to humans is unclear as yet.

12 Jan 2021

Structure of SARS-CoV-2 cytoplasmic tail uncovered

The virus's cytosolic tail also interacts with the host cell to promote its entry into the endoplasmic reticulum (ER). A new study appearing on the bioRxiv preprint server elucidates the conformation of this region of the virus, which will help understand how its form is related to its function in viral entry.

12 Jan 2021

Effect of mutations in the South African SARS-CoV-2 variant on transmission and neutralization

One such strain is the South African 501.V2 and UK B1.1.7 strains, which have been isolated from many countries and seem to spread faster than the ancestral strain. A preprint that recently appeared on the bioRxiv server reports the computational structure of this strain and the possible effect of the mutations on infectivity and neutralization.

12 Jan 2021

Antigenic "supersite" could improve design of COVID-19 vaccines

Researchers in the United States have defined an antigenic “supersite” within the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have important implications for the design of vaccines to protect against coronavirus disease 2019 (COVID-19).

12 Jan 2021

Hypoxia signaling pathway could lead to COVID-19 treatments

Researchers in Spain have demonstrated that studying the hypoxia signaling pathway could provide opportunities for treating coronavirus disease 2019 (COVID-19).

12 Jan 2021

Spike Protein News and Research

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

Lab study reveals effective treatment for COVID-19

Study suggests SARS-CoV-2 could affect aquatic wildlife

New tests may help reveal the transcriptome of SARS-CoV-2 and predict disease course

No inflammation of cerebrospinal fluid in COVID-19 patients with neurological features, study finds

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

Could intranasal SARS-CoV-2 vaccines be a practical alternative to intramuscular shots?

Study identifies features of potent SARS-CoV-2 neutralizing antibodies

Moderna to develop three new mRNA-based vaccines against HIV, influenza, and the Nipah virus

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

New UK-derived SARS-CoV-2 variant does not affect neutralizing antibodies efficiency, study says

Could fenofibrate be an effective antiviral against SARS-CoV-2?

Researchers develop novel antibody fragments against SARS coronavirus-2

New publication describes DiosCURE’s multivalent single-chain antibodies to inactivate SARS-CoV-2

Antibody-Fc-mediated innate immunity shapes COVID-19 severity

Intranasal vaccination effectively reduces viral shedding of SARS-CoV-2 in monkeys

Structure of SARS-CoV-2 cytoplasmic tail uncovered

Effect of mutations in the South African SARS-CoV-2 variant on transmission and neutralization

Antigenic "supersite" could improve design of COVID-19 vaccines

Hypoxia signaling pathway could lead to COVID-19 treatments

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News